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Table 1
Overall survival rate (OS) and thalassemia-free survival rate (TFS) of BMT
and PBSCT stratiﬁed by disease classes:
BMT PBSCT
OS 1 y 2 y 5 y p-value OS 1 y 2 y 5 y p-value
I 92.3% 92.3% 90.1% .148 I 81.7% 80.7% 78.0% .011
II 79.7% 79.7% 77.6% II 87.9% 85.2% 79.5%
III 79.7% 78.3% 76.3% III 75.1% 69.5% 64.0%
TFS 1 y 2 y 5 y p-value TFS 1 y 2 y 5 y p-value
I 80.8% 80.8% 78.8% .167 I 78.9% 77.9% 75.2% <.001
II 68.4% 67.0% 65.4% II 85.5% 81.9% 76.1%
III 67.7% 64.7% 60.6% III 66.0% 59.7% 55.2%
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advantage over relapse diagnosed by clinical means in pa-
tients with relapsed lymphoma undergoing subsequent
auto-SCT.
Methods: In an attempt to answer the above question, we
grouped all the patients with relapsed lymphoma (Hodgkin
and non-Hodgkin’s lymphoma) who were referred to our
center for auto-SCT between January 1, 2007 till December
31, 2012 in Cohort A (Relapse diagnosed by radiological
surveillance) and Cohort B (Relapse diagnosed by clinical
means based on new symptoms and examination ﬁndings).
All patients had biopsy proof of relapse prior to salvage
chemotherapy.
The primary objectives were post-transplant relapse and
disease-free survival. Kaplan-Meier and the Log-rank test
were used for analysis.
Results: A total of 133 patients were included in the analysis,
with 74 patients in the radiographic screening Cohort A and
59 patients in the symptomatic/clinical relapse Cohort B.
Clinically important patient characteristics were similar be-
tween the two cohorts. The clinical stage at relapse leading to
transplant, salvage chemotherapy regimens and number of
cycles used prior to transplant, response to salvage chemo-
therapy, time to transplant, and 100-day post-transplant
outcomes were not statistically different between the two
groups. Nine patients died in cohort A, 5 of whom were due
to disease relapse. Thirteen patients died in cohort B, 7 due to
disease relapse. The 3-year relapse-free survival was 54% in
Cohort A and 46% in Cohort B. There was no statistically
signiﬁcant difference in the relapse-free-survival between
the two cohorts (p¼.26). The median duration of follow-up
for Cohort A was 23.7 months (range 0.61-73.11) and for
Cohort B was 13.57 months (range 0.36-57.0). When the
same analysis was conducted in patients with non-Hodgkin’s
lymphoma (excluding data for Hodgkin’s disease), the results
were similar. Median duration of survival was not reached, so
no attempt was made to comment on overall survival in this
small cohort with few events to analyze.
Conclusions: In this single center study, we showed that
routine radiological surveillance after completion of
chemotherapy did not improve relapse-free-survival in pa-
tients with lymphoma undergoing subsequent auto-SCT. We
plan to start a prospective study exploring the role of routine
radiological surveillance after auto-SCT in patients with
lymphoma to answer another important question.137
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Introduction: HSCT is the treatment of choice for patients
with thalassemia. Here, we report our hematopoietic stem
cell transplantation experience in the treatment of thalas-
semia major patients, using PBSCT versus BMT.Patients and Methods: From 1992 to 2013, 574 patients
underwent HSCT in our centre. 221 patients received HSCT
from BMT and 353 patients from PBSCT. The median age in
the BMT group was 7years (2-26years) and in the PBSCT
group was 8 years (2-29 years) (P-Value¼.001). In BMTgroup
89(40.3%) patients were class III whereas in PBSCT group
were 121(34.3%) (P-Value¼.196).
Results: Acute graft versus host disease (GvHD) occurred in
141(63.80%) and 253(71.70%) of patients in the BMT and
PBSCT, respectively (P-Value¼.048). Chronic GvHD was
19.30% in the BMTand 32.70% in the PBSCT (P-Value¼.001) in
survivors after 100 days. With a median follow-up of
50months, the 5-year thalassemia-free survival rate (TFS) of
BMT and PBSCT were 76.3% and 67.5%, respectively (P-Val-
ue¼.294). The 5-year overall survival rate (OS) in BMT and
PBSCT were 80.1% and 73.8%, respectively (P-Value¼.119).
The rejection was 16.3% and 6.5% in BMT and PBSCT,
respectively. The most common causes of death were GvHD
and infections in both groups. TFS and OS results stratiﬁed by
disease class showed better survival rates in lower classes
(Table1).
Conclusion: The PBSCT was an easier procedure for donors
with lower cost compared with BMT. Acute GvHD was
slightly more in PBSCT but chronic GvHDwas more frequent.
Chronic GvHDwas alleviated over time and also it seems that
the rejection is lower in PBSCT. These results show that HSCT
should be considered for lower class of thalassemia and
PBSCT is an acceptable alternative.138
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Racial and ethnic disparities have been reported in the uti-
lization of autologous and allogeneic BMT and in the avail-
ability of allogeneic donors for minority populations. In
addition, adults in general, and minorities in particular, have
low rates of participation in research studies. Several factors
may lead to under-utilization of BMT and lack of clinical trial
participation, such as differential access to care, co-morbid-
ities, tobacco use, obesity and mistrust of the medical system
due to previous unethical practices with minorities in
research studies. We investigated the low rates of minorities
1) referred for BMT consultation, 2) undergoing BMT as
therapy, and 3) participating in biospecimen and survey
research at a single U.S. center by performing a population
based analysis using New York State (NYS) Department of
Persons aged 18-75 years
European
American
African
American
Other
US Census data 2007-2010,
8 counties of WNY
90% 9.5% <1%
NYS DOH Cancer Registry,
2005-2010 cases of acute
and chronic leukemia,
lymphoma and myeloma in
8 counties of WNY
91% 8% <1%
Total Referrals to BMT program
at RPCI 2005-2011
90.5% 7% 2.5%
Total Referrals to BMT program
at RPCI 2005-2011, and resided
in 1 of 8 counties in WNY
90% 8% 2%
All patients who received a BMT
at RPCI 2005-2011
92% 6% 2%
Received a BMT at RPCI, 2005-2011
and resided in 1 of 8 counties
in WNY
91% 7% 2%
Proportion of BMT referrals who
participated in biospecimen
research, 2005-2011
95% 95% 88%
Proportion of BMT referrals who
participated in survey research,
2005-2011
70% 37% 67%
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Data. From 2005-2011, 1106 patients aged 18-75 years were
referred to our center for BMT consultation, the majority of
whom (74%) reside in the 8 counties of Western NY (WNY).
The Table compares the race of BMT patients, referrals,
cancer cases and general population estimates. Reasons for
not receiving a BMT differed by race with European Ameri-
cans (EAs) mostly due to patient decision (20%) and African
Americans (AAs) mostly due to death before BMT (16%). We
further examined patient characteristics which might inﬂu-
ence referral for BMT consultation and utilization of BMT by
conducting a retrospective cohort study of the 1106 BMT
referrals who participated in our Databank and Bio-Re-
pository (DBBR) biologic specimen banking (one-time blood
sample collection) and epidemiologic questionnaire (written
at 9th grade level, 45 minutes to complete). As shown in the
Table, participation in biospecimen research did not vary by
race, however AAs were signiﬁcantly less likely to participate
in survey research than EAs and other races. While the mi-
nority rates of referrals and BMTmay appear low, they reﬂect
the race distribution of the cancer cases and general popu-
lation in WNY. AAs are equally likely to participate in bio-
specimen banking, but further study is needed to elucidate
reasons for lower participation in survey research.139
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Themaximum tolerated dose (MTD) of lomustine when used
in combinationwith etoposide, ara-C, andmelphalan (LEAM)in a conditioning regimen prior to autologous hematopoietic
stem cell transplantation (HSCT) for lymphoma is unknown.
We performed a phase 1 clinical trial with traditional 3+3
design to determine the MTD of lomustine administered on
D-4 followed by etoposide (1 g/m2 D-3), ara-C (4g/m2 D-2),
and melphalan (140 mg/m2 D -1). Dose-limiting toxicity
(DLT) was deﬁned as grade 3 or 4 non-hematologic or in-
fectious toxicity, delayed engraftment beyond D+30 or death
from any cause. The initial dose of lomustinewas 200mg/m2
(L200 cohort), increased by 200 mg/m2 at each subsequent
cohort (L400, etc). Because L400 exceeded MTD, a third
cohort was created with 300 mg/m2 of lomustine (L300).
Fourteen subjectes entered the trial being 9 with Hodgkin
lymphoma, 2 with mantle cell lymphoma, 1 with diffuse
large B-cell lymphoma, 1 with follicular lymphoma and 1
with peripheral T-cell lymphoma. Subjects were either in PR
(n¼6) or CR (n¼8) after the most recent salvage theapy.
Median age of subjects was 36 years. Six patients were
treated with L200 (1 DLT, death by sepsis), two patients were
treated with L400 (2 DLT, grade 4 gastrointestinal toxicity)
and 6 patients were treated at an intermediate dose of 300
mg/m2 (L300, 1 DLT, neurological grade 4, reversible) and
L300 was declared the MTD. A median number of 6.91 CD34
cells/kg (range 1.37-18.8) were infused. The average duration
of neutropenia (neutrophils <500/mm3) was 7.8 days, lower
than the historical control of 13 days with cyclophospha-
mide, BCNU, and etoposide (CBV) conditioning. Neutrophils
and platelet engraftment occurred on average at day 10 and
12 respectively. We concluded that 300mg/m2 is the MTD of
lomustine in combination with etoposide, ara-C and
melphalan (LEAM) conditioning in autologous-HSCT in pa-
tients with lymphoma. More detailed toxicity proﬁle and
anti-lymphoma activity will be obtained from ongoing
expansion of the L300 cohort. LEAM is a simple conditioning
regimen with rapid dosing, consequent short period of
neutropenia and acceptable toxicity.140
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Background: Plerixafor (Mozobil) plus G-CSF is an FDA-
approved strategy to mobilize hematopoietic stem cells
(HSCs) in patients (pts) with NHL and Multiple Myeloma. We
report our institutional experiencemobilizing HSCs with and
without plerixafor in pts with NHL and HL.
Methods: We collected data on all NHL (n¼85) and HL
(n¼44) pts who underwent mobilization without chemo-
therapy between 2010 and 2012 at Ohio State University
under IRB approved protocols. Our standard is plerixafor on
day 4 of G-CSF in pts who received radiation, 10 cycles of
chemotherapy, are age 60, or on day 5 to pts who had a
CD34 count of <10/mL that morning. Our target CD34+ cell
yield is >5x106 /kg recipient weight, with a minimum of
>2x106 /kg. Factors associated with sufﬁcient mobilization
were evaluated using univariate logistic regressionmodels as
well as graphical analyses.
